^
Association details:
| Biomarker: | RAB5A expression |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Perjeta (pertuzumab) (HER2 dimerization inhibitor) + Kadcyla (ado-trastuzumab emtansine) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer
Published date:
11/05/2021
Excerpt:
Correlation between RAB5A expression and T-DM1 sensitivity is confirmed in breast cancer patients treated with trastuzumab emtansine/pertuzumab in the I-SPY2 trial (NCT01042379)...The p-value for the interaction between RAB5A expression and treatment was 0.02 and remained <0.05...
DOI:
https://doi.org/10.1038/s41467-021-26018-z
Trial ID:
